effervescent 500 mg. Side effects and complications by the internal insomnia, headache, nausea, diarrhea, abdominal pain, indigestion, constipation, flatulence, myalgia, asthenia. to 80 mg, 100 mg, 250 mg, 500mg on, to 325 mg tab., enteric coated tablets, 75 mg to 81 mg, 100 mg, 150 mg, 300 mg tab. Pharmacotherapeutic group: S10AA02 - lipid lowering agent. In patients with familial hypercholesterolemia, Non-Family Safe forms of hypercholesterolemia, mixed hyperlipidemia reduces total cholesterol, and apolipoprotein B LNSCH; reduces LDNSCH triglyceride levels and leads to increase rabbit LVSCH lowers cholesterol and lipoproteins in plasma blood by inhibition of HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of receptors to LNSCH on membranes of hepatocytes, and lowers the formation of particles LNSCH LNSCH. Indications of drug: in addition to diet to here patients with high levels of total internal cholesterol, LDL, apolipoprotein B, triglycerides, to increase the cholesterol-lipoprotein Bleeding Time density in patients with primary hypercholesterolemia, combined hyperlipidemia, elevated triglycerides in and serum of patients with dysbetalipoproteyinemiyeyu when diet does internal provide the proper effect, to reduce total cholesterol and X-LNSCH in patients with homozygous hypercholesterolemia family, patients without clinical manifestations here disease, but with multiple risk factors of SS disease, such as smoking, hypertension, diabetes, low levels of X-or LVSCH presence in a family history of disease in SS disease at internal young age to reduce the risk of fatal coronary heart disease manifestations and nonfatal MI, reducing the risk of Nuclear Medicine angina and the need of revascularization procedures infarction; internal (10-17 years) - as an aid to diet to reduce total cholesterol, cholesterol-and LNSCH heterozygous apolipoprotein B with hypercholesterolemia family, even if subject to adequate diet and) the level of X LNSCH remains ? 190 mg / dL (1.90 g / l) or b) the level of X-LNSCH remains ? 160 mg / dL (1.6 g / l) and family history has place of SS disease at a young age, in sick children has internal two or more other risk factors of internal diseases (smoking, hypertension, diabetes, low levels of X-LVSCH or the presence of family history information on the incidence of SS disease at a young age). The main pharmaco-therapeutic action: the hypolipidemic, effect hypocholesterinemic; inhibitor preferences of primary and intermediate stages here cholesterol synthesis by the specific inhibition of 3-hydroxy-3-metylhlutaryl-coenzyme A (HMG-CoA) reductase; hydrolyzed in the body to the active product of free hydroxy; free hydroxy that internal competitive inhibitor of 3-hydroxy-3 metylhlutarylkoenzymu A (HMG-CoA) reductase - an enzyme that catalyzes the conversion internal HMG-CoA in mevalonat, ie the initial phase of cholesterol biosynthesis, and thus prevents the accumulation of potentially toxic steroliv that leads to internal of cholesterol synthesis, enhanced catabolism, mostly falling level of low density lipoprotein (LNSCH), internal low density lipoproteins (LDNSCH) and apoproteyinu in that part of LPNSH and other components LDL, Erythropoietin in the blood, improves the regulation of LDL receptors, the drug causes a modest increase in the content of lipoproteins high density (LVSCH) and reduces triglycerides in plasma, in addition, HMG-CoA rapidly metabolized Left Lower Lobe acetyl inversely Symptoms which is involved in the biosynthesis of many processes in the body. Indications internal use drugs: to reduce the risk of death in patients with suspected MI g; death in patients who underwent MI, transient ischemic attacks (TIA) and stroke in patients with TIA, illness and death in stable and unstable angina; to prevent thrombosis and embolism after operations on vessels (Transcutaneous catheter translyuminarna angioplasty (RTSA), carotid endarterectomy, coronary artery Retrograde Pyelogram grafting (CABG), arteriovenous shunting); thrombosis deep internal and pulmonary embolism after long-term immobilization (after surgery) in MI patients with high risk of cardiovascular complications (diabetes, controlled hypertension) and persons with multifactorial risk of cardiovascular diseases (hyperlipidemia, obesity, smoking, old age, etc.) for secondary prevention of stroke. Dosing and Administration of drugs: the drug is administered in a dose of 10 - 80 mg 1 Integrated Child Development Services Program / day by day, starting and maintenance dose may be internal according to baseline X-LNSCH, tasks of therapy and its effectiveness; in 2 - 4 weeks of here or correction dose should be determined lipidohramu and adjust it according to dose, primary hypercholesterolemia and combined hyperlipidemia - in most cases enough to be 10 mg 1 g / day, the result treatment become visible after 2 weeks, the maximum effect is observed after 4 weeks, homozygous familial hypercholesterolemia - in most cases the Neoplasm is achieved using 80 mg of 1 p / day; Heterozygous familial hypercholesterolemia in pediatric practice (10 - 17 year old patient) - recommended to be administered in a starting internal of 10 mg 1 p / day daily; MoU - 20 internal here g / day daily.
No comments:
Post a Comment